Halozyme Therapeutics (HALO)
38.18
+0.37 (0.98%)
Upcoming Events
Latest Headlines
Form 4 HALOZYME THERAPEUTICS, For: Apr 16 Filed by: LaBarre Michael J.
April 17, 2024 7:23 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
April 17, 2024 4:04 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
April 16, 2024 4:02 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Mar 26 Filed by: LaBarre Michael J.
March 26, 2024 7:39 PM - SEC Filing
Form ARS HALOZYME THERAPEUTICS, For: Dec 31
March 15, 2024 4:52 PM - SEC Filing
Form DEFA14A HALOZYME THERAPEUTICS,
March 15, 2024 4:21 PM - SEC Filing
Form DEF 14A HALOZYME THERAPEUTICS, For: Dec 31
March 15, 2024 4:07 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Mar 12 Filed by: LaBarre Michael J.
March 13, 2024 5:22 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
March 13, 2024 4:15 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
March 12, 2024 4:12 PM - SEC Filing
Form PRE 14A HALOZYME THERAPEUTICS, For: Dec 31
March 4, 2024 4:14 PM - SEC Filing
TD Cowen Starts Halozyme Therapeutics (HALO) at Outperform, 'I Can See Your Halo…But I Never Really Had A Doubt'
February 29, 2024 5:30 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Feb 27 Filed by: LaBarre Michael J.
February 28, 2024 6:50 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
February 28, 2024 4:10 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: LaBarre Michael J.
February 27, 2024 5:13 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: Snyder Mark Howard
February 27, 2024 5:11 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: LaBrosse Nicole
February 27, 2024 5:07 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: Torley Helen
February 27, 2024 5:03 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
February 27, 2024 4:10 PM - SEC Filing
Halozyme to Participate in Upcoming Investor Conferences
February 27, 2024 8:30 AM - PR NewsWire
Halozyme Therapeutics (HALO) PT Raised to $50 at H.C. Wainwright
February 21, 2024 6:44 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: LaBarre Michael J.
February 20, 2024 6:59 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: Snyder Mark Howard
February 20, 2024 6:56 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: LaBrosse Nicole
February 20, 2024 6:53 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: Torley Helen
February 20, 2024 6:50 PM - SEC Filing
Form 10-K HALOZYME THERAPEUTICS, For: Dec 31
February 20, 2024 4:09 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Feb 20
February 20, 2024 4:04 PM - SEC Filing
Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c ; Offers Guidance
February 20, 2024 4:03 PM - StreetInsider
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
February 20, 2024 4:01 PM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: Feb 15 Filed by: LaBarre Michael J.
February 16, 2024 5:47 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 15 Filed by: LaBrosse Nicole
February 16, 2024 5:42 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 15 Filed by: Torley Helen
February 16, 2024 5:39 PM - SEC Filing
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: VANGUARD GROUP INC
February 13, 2024 5:10 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 10 Filed by: LaBarre Michael J.
February 13, 2024 4:18 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 10 Filed by: LaBrosse Nicole
February 13, 2024 4:16 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Feb 10 Filed by: Torley Helen
February 13, 2024 4:13 PM - SEC Filing
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: Artisan Partners Limited Partnership
February 12, 2024 7:02 AM - SEC Filing
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
February 8, 2024 4:30 PM - PR NewsWire
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: Invesco Ltd.
February 1, 2024 3:52 PM - SEC Filing
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024 4:15 PM - PR NewsWire
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: BlackRock Inc.
January 23, 2024 11:53 AM - SEC Filing
Full Article List
